Sementis aims to become a global leader in the development and commercialization of vaccines targeted at the treatment or prevention of allergies. Using its proprietary Sementis Copenhagen Vector (SCV) platform technology, the Company’s primary focus is to develop a vaccine to prevent allergic reactions to peanuts for which no vaccine currently exists - more than 1% of the general population and 3% of children in western countries suffer from allergies to peanuts.
Sementis is seeking funding to enable the completion of its pre-clinical work including immunogenicity, process development, manufacturing of clinical batches of vaccine and toxicology studies for the peanut vaccine, and to finance the phase I clinical trials for the peanut vaccine.
The choice you make above will help our platform display content that is best suited to you
Welcome to the new Wholesale Investor platform. Please use your existing log in details to access the site. Alternatively feel free to use the "Login with LinkedIn" or "Sign in with Google" buttons.
Enter your email to reset your password.